Advertisement

Advertisement

Journal Spotlight

Kidney Cancer

KEYNOTE-564: Adjuvant Pembrolizumab Improves Overall Survival vs Placebo in Renal Cell Carcinoma

Matthew Stenger  /  May 25, 2024

As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, FASCO, of Dana-Farber Cancer Institute and Harvard Medical School, and colleagues, the third prespecified interim analysis of overall survival in the phase III KEYNOTE-564 trial has shown significant benefit with adjuvant pe...

Lung Cancer

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK-Positive NSCLC

Matthew Stenger  /  May 25, 2024

As reported in The New England Journal of Medicine by Yi‑Long Wu, MD, of Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and colleagues, the phase III ALINA trial has shown significantly improved disease-free survival with adjuvant alectinib vs platinum-based chemotherapy ...

Gynecologic Cancers

Noninferiority of Simple vs Radical Hysterectomy for Pelvic Recurrence in Low-Risk Cervical Cancer

Matthew Stenger  /  May 25, 2024

As reported in The New England Journal of Medicine by Marie Plante, MD, of Centre Hospitalier Universitaire de Quebec, and colleagues, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in the frequency of pelvic recurrence in women with low-risk cervical can...

Issues in Oncology

Study Finds the Financial Hardship Caused by Cancer Is Long-Lasting for Many Working-Age Adults

Jo Cavallo  /  May 25, 2024

When combined with high out-of-pocket costs for cancer care, nearly 60% of working-age cancer survivors report experiencing at least one type of financial hardship, including being unable to afford medical bills, distress and worry, or delaying or forgoing needed care because of cost, according to s...

Bladder Cancer

Enfortumab Vedotin-ejfv Plus Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced Urothelial Cancer

Matthew Stenger  /  May 10, 2024

As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody–drug conjugate enfortumab vedotin-ejfv, which is dire...

Colorectal Cancer

Cell-Free DNA Blood-Based Test and Next-Generation Multitarget Stool DNA Test in Colorectal Cancer Screening

Matthew Stenger  /  May 10, 2024

In two studies reported in The New England Journal of Medicine, investigators found that a cell-free DNA (cfDNA) blood-based test (ECLIPSE study)1 and a next-generation multitarget stool DNA test (BLUE-C study)2 both showed high sensitivity for colorectal cancer and high specificity for advanced neo...

Immunotherapy
Lung Cancer

Use of Combination Immunotherapy Before Lung Cancer Surgery

The ASCO Post Staff  /  March 25, 2024

Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents seemed to outperform durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center, Ho...

Prostate Cancer

Brachytherapy Boost May Decrease the Duration of Androgen-Deprivation Therapy for High-Risk Prostate Cancer

Manuj Agarwal, MD  /  March 25, 2024

The optimal management of high-risk prostate cancer remains a topic of ongoing investigation. The quest for therapy that maximizes cancer control while minimizing toxicity is constant. Over the past decade, there has been mounting evidence that the addition of a brachytherapy boost to external-beam...

Cardio-oncology

Relationship Between Second Malignant Neoplasm and Heart Disease Studied in Childhood Cancer Survivors

Susan Reckling, MA  /  March 10, 2024

In a French study of more than 7,000 childhood cancer survivors, published in JACC: CardioOncology, Thibaud Charrier, PhD, of the Université Paris-Saclay, Villejuif, France, and colleagues reported that the occurrence of a second malignant neoplasm among these childhood cancer survivors seemed to be...

Gynecologic Cancers

OVHIPEC-1 Trial: Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Improves Survival in Advanced Ovarian Cancer

Matthew Stenger  /  January 25, 2024

The final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall survival benefits at 10 years in women with advanced ...

Cardio-oncology

International Collaborative Research Efforts in Cardio-Oncology

Susan Reckling, MA  /  January 25, 2024

At the 2023 Global Cardio-Oncology Symposium (GCOS), international experts explored the ongoing collaborative efforts to improve the cardiovascular health of patients being treated for cancer as well as the bidirectional challenges of translating basic research to clinical care. Focus on Basic and ...

CNS Cancers

First-Line Dabrafenib Plus Trametinib vs Standard Chemotherapy for Pediatric Low-Grade Glioma With BRAF V600 Mutations

Matthew Stenger  /  November 25, 2023

As reported in The New England Journal of Medicine by Eric Bouffet, MD, of the Hospital for Sick Children, Toronto, and colleagues, a phase II trial has shown a significant improvement in objective response rate and other efficacy outcomes with first-line dabrafenib plus trametinib vs standard chemo...

Prostate Cancer

PROpel Trial: Olaparib Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer Unselected for HRR Mutation Status

Matthew Stenger  /  November 25, 2023

As reported in The Lancet Oncology by Fred Saad, MD, of the Centre Hospitalier de l’Université de Montréal, and colleagues, the final prespecified overall survival analysis of the phase III PROpel trial has shown no significant benefit with the addition of first-line olaparib to abiraterone in patie...

Lung Cancer

Addition of Tumor Treating Fields Therapy to Standard Systemic Therapy Improves Survival in Metastatic NSCLC after Progression on Platinum-Based Therapy

Matthew Stenger  /  November 10, 2023

In a phase III trial (LUNAR) reported in The Lancet Oncology, Ticiana Leal, MD, Winship Cancer Institute at Emory University, and colleagues found that the addition of Tumor Treating Fields (TTFields) therapy to standard systemic therapy improved overall survival in patients with metastatic non-smal...

Cardio-oncology

Diagnosis of Cardiovascular Disease and Risk of Subsequent Incident Cancer Diagnosis

Matthew Stenger  /  October 25, 2023

In a retrospective cohort study reported in JACC: CardioOncology, Caitlin F. Bell, MD, of the Division of Cardiovascular Medicine, Stanford University School of Medicine, and colleagues found that persons with a diagnosis of cardiovascular disease (CVD) were more likely to have a subsequent incident...

Skin Cancer

Ipilimumab Plus Nivolumab May Improve Outcomes in Refractory Metastatic Melanoma, Study Suggests

The ASCO Post Staff  /  September 25, 2023

Researchers have discovered that the combination of the CTLA-4 inhibitor ipilimumab and the PD-1 inhibitor nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent study conducted by the SWOG Cancer Research Network and ...

Issues in Oncology

Patterns in Early-Onset Cancer in the United States From 2010 to 2019

Matthew Stenger  /  October 10, 2023

In a study using SEER (Surveillance, Epidemiology, and End Results) registry data reported in JAMA Network Open, Daniel Q. Huang, MBBS, MMED, of the National University of Singapore, and colleagues found that the incidence of cancer among U.S. persons up to age 50 (early-onset cancer) increased sign...

Kidney Cancer

First-Line Pembrolizumab Plus Lenvatinib Active in Advanced Non–Clear Cell Renal Cell Carcinoma

Matthew Stenger  /  September 25, 2023

In a phase II trial (KEYNOTE-B61) reported in The Lancet Oncology, Laurence Albiges, MD, PhD, of Gustave Roussy, Paris–Saclay University, Villejuif, France, and colleagues found that first-line pembrolizumab plus lenvatinib produced durable responses in patients with advanced non–clear cell renal ...

Lung Cancer

Addition of Nivolumab to Stereotactic Ablative Radiotherapy in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC

Matthew Stenger  /  September 10, 2023

In a phase II trial (I-SABR) reported in The Lancet, Joe Y. Chang, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the addition of immunotherapy with nivolumab to stereotactic ablative radiotherapy (SABR) improved...

Breast Cancer
Cardio-oncology

Association of Lifestyle and Cardiovascular Risk Factors With Hospitalization for Heart Failure Subtypes in Breast Cancer Survivors

Matthew Stenger  /  April 25, 2022

In an analysis from the Women’s Health Initiative reported in JACC: CardioOncology, Kerryn W. Reding, PhD, MPH, RN, of the University of Washington at Seattle, and colleagues, identified the incidence of hospitalization for heart failure among postmenopausal breast cancer survivors. They reported th...

Survivorship
Solid Tumors
Cardio-oncology

Cardiovascular Mortality and Cancer Mortality Over Time Among Cancer Survivors

Matthew Stenger  /  August 25, 2022

In an English retrospective cohort study reported in JACC: Cardio-Oncology, Helen Strongman, PhD, of the Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, and colleagues found that cardiovascular mortality ultimately exceeded mortality from common p...

Prostate Cancer
Genomics/Genetics

Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Matthew Stenger  /  August 25, 2023 - Supplement: Genitourinary Oncology Almanac

As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the e...

Breast Cancer

ASCO-CAP Guideline Update Confirms Previous Recommendations for HER2 Testing in Breast Cancer

Emily A. Kuhl, PhD  /  July 25, 2023

In partnership with the College of American Pathologists (CAP), ASCO has affirmed findings from its 2018 practice guideline on the use of HER2 testing in breast cancer. Notably, the ASCO/CAP expert panel found there is currently no justification for a new designation of HER2 test results for patient...

Head and Neck Cancer

Investigators Evaluate the Effect of Body Mass Index on Outcomes in Patients With Head and Neck Cancer

The ASCO Post Staff  /  July 25, 2023

Investigators reported that patients with head and neck cancer who had an overweight body mass index (BMI) may have had better outcomes, longer overall and progression-free survival, and lower rates of locoregional failure than those patients with a normal or obese BMI, according to a recent study p...

Gastroesophageal Cancer
Immunotherapy

Addition of Tislelizumab to Chemotherapy Improves Survival in Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Matthew Stenger  /  July 10, 2023

As reported in The Lancet Oncology by Jianming Xu, MD, of Fifth Medical Center, Chinese PLA General Hospital, Beijing, corresponding author Harry H. Yoon, MD, of the Department of Oncology, Mayo Clinic, Rochester, and colleagues, an interim analysis of the phase III RATIONALE-306 trial has shown imp...

COVID-19

Certain Cancers Will Likely Rise Exponentially Because of COVID-19 Screening Delays, Study Predicts

The ASCO Post Staff  /  June 25, 2023

Delays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases that could have been caught earlier with screening. These cases may now be diagnosed at later stages, placing an increased burden on an already-strained health-care system, according to a...

Immunotherapy

Immune Checkpoint Inhibitors Show Promise for People Living With HIV

Matthew Stenger  /  June 25, 2023

New research involving people living with HIV treated with immune checkpoint inhibitors has provided valuable insights into the safety and efficacy of immunotherapy in this historically excluded population, according to data published in the Journal of Clinical Oncology.1 The real-world data analysi...

Breast Cancer

Interruption of Endocrine Therapy to Attempt Pregnancy in Women With Hormone Receptor–Positive Early Breast Cancer

Matthew Stenger  /  June 10, 2023

In a study reported in The New England Journal of Medicine, Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and colleagues found that temporary interruption of adjuvant endocrine therapy to attempt pregnancy was not associated with increased short-term risk of breast cancer events among ...

Solid Tumors
Genomics/Genetics

Tumor Genomic Profile and Risk for Arterial Thromboembolism in Patients With Solid Cancer

Matthew Stenger  /  May 25, 2023

  In a single-institution study reported in JACC: CardioOncology, Stephanie Feldman, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that somatic KRAS and STK11 alterations were associated with increased risk of arterial thromboembolism in patients with solid tumors, irrespectiv...

Solid Tumors

Survival in Patients With Neuroblastoma on Reduced Therapy as a Result of Change in COG Risk Stratification

Matthew Stenger  /  May 25, 2023

In an analysis recently reported in the Journal of Clinical Oncology,1 Bender et al found that “excellent” survival outcomes were achieved in patients receiving reduced treatment for neuroblastoma as a result of reassignment to intermediate risk from high risk based on a change in the minimum age fo...

COVID-19

American College of Surgeons Evaluates the Impact of COVID-19 Pandemic on National Cancer Database Reporting

The ASCO Post Staff  /  May 25, 2023

New research from the American College of Surgeons (ACS) outlines significant ways that the COVID-19 pandemic destabilized usual patterns of cancer care, as reported in the National Cancer Database (NCDB). The NCDB is one of the largest cancer registries in the world and is used by thousands of hosp...

Issues in Oncology

Radiation Oncology Workforce Expected to Remain Stable Through 2030

The ASCO Post Staff  /  May 25, 2023

A new analysis of the U.S. radiation oncology workforce projects a relative balance between the supply of radiation oncologists and the demand for radiation therapy services through 2030.1 The report was produced by Health Management Associates (HMA), a consulting firm commissioned by the American S...

Circulating Tumor DNA Identified Prior to and During Treatment Is Associated With Poorer Outcomes in Primary CNS Lymphoma

Matthew Stenger  /  May 25, 2023

In a collaborative study from the University of Freiburg and Stanford University reported in the Journal of Clinical Oncology, Jurik A. Mutter, BSc, of the Faculty of Medicine, University of Freiburg, and colleagues found that circulating tumor DNA (ctDNA) identified prior to and during treatment ...

Lung Cancer

Detection of Early Emphysema During Lung Cancer Screening: Opportunities to Optimize Health

Matthew Stenger  /  May 10, 2023

In an article in Annals of the American Thoracic Society, James L. Mulshine, MD, of the Center for Healthy Aging, Department of Medicine, Rush University, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening ...

Multiple Myeloma
Immunotherapy

Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma

Matthew Stenger  /  March 25, 2023

As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed chime...

Lung Cancer

Yale Study Indicates Older Patients Are Excluded From Progress Against Lung Cancer

The ASCO Post Staff  /  February 25, 2023

The widespread use of immune checkpoint inhibitors has led to significant benefits in younger patients with advanced lung cancer; however, older patients have not experienced similar survival benefits, according to research from Yale Cancer Center. The study was published in JAMA Oncology.1 “Ther...

Breast Cancer
Immunotherapy

DESTINY-Breast03: T-DXd Improves Overall Survival vs T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer

Matthew Stenger  /  March 25, 2023

As reported in The Lancet by Sara A. Hurvitz, MD, of the David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with fam-trastu...

Lung Cancer
Genomics/Genetics

Sotorasib Improves Progression-Free Survival vs Docetaxel in Previously Treated Advanced NSCLC With KRAS G12C Mutation

Matthew Stenger  /  March 25, 2023

As reported in The Lancet by ­Adrianus Johannes de Langen, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, and colleagues, the phase III CodeBreaK200 trial has shown a small but significant improvement in progression-free survival with sotorasib vs docetaxel in previously treated advanced n...

Issues in Oncology

Association of Baseline and Subsequent Cardiovascular Health Metrics to Risk for Incident Cancers

Matthew Stenger  /  March 25, 2023

In an analysis from the French GAZEL study reported in JACC: CardioOncology, Thomas Van Sloten, MD, PhD, of the Université Paris Cité, Institut National de la Santé et de la Recherche Médicale, Paris, and colleagues found that better cardiovascular health (CVH) scores at baseline and improvement in ...

Issues in Oncology

Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among U.S. Patients With Cancer

Matthew Stenger  /  March 25, 2023

In an analysis reported in JACC: CardioOncology, Cenjing Zhu, MPhil, of the Department of Chronic Disease Epidemiology, Yale University, and colleagues found that Black patients with cancer in the United States were at increased risk of all-cause mortality and cardiovascular (CVD) mortality compared...

Prostate Cancer
Genomics/Genetics

Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Matthew Stenger  /  March 25, 2023

As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the e...

Breast Cancer

Adjuvant Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation in Early Breast Cancer: 10 Year Outcomes of Phase III Study

Matthew Stenger  /  March 25, 2023

As reported in The Lancet Oncology by Vratislav Strnad, MD, PhD, of University Hospital Erlangen and Comprehensive Cancer Center Erlangen, Germany, and colleagues, 10-year outcomes in a phase III GEC-ESTRO (Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology) trial ...

Hematologic Malignancies

Zanubrutinib Improves Progression-Free Survival vs Ibrutinib in Relapsed or Refractory CLL or SLL

Matthew Stenger  /  March 25, 2023

As reported in The New England Journal of Medicine by Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute and Harvard University, and colleagues, the phase III ALPINE trial has shown significantly better progression-free survival with zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibito...

Gynecologic Cancers

Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer With High FRα Expression

Matthew Stenger  /  March 10, 2023

As reported in the Journal of Clinical Oncology by Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, and colleagues, the phase II SORAYA study has shown activity of mirvetuximab soravtansine-gynx, an antibody-drug conjugate targeting folate receptor α (FRα), in women with platinum-resist...

Colorectal Cancer
Genomics/Genetics

KRYSTAL-1 Confirms Activity of Adagrasib in KRAS G12C–Mutated Metastatic Colorectal Cancer and Highlights Need for Randomized Controlled Trials

Marwan Fakih, MD  /  February 10, 2023

KRAS G12C–mutated colorectal cancer represents 3% to 4% of metastatic colorectal cancers. Like other KRAS-mutated metastatic colorectal cancers, this group of patients represents a patient population with an unmet need, with limited options beyond two lines of therapy. In contrast to other KRAS muta...

Multiple Myeloma

Significant Benefit With Addition of Daratumumab to Bortezomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma

Matthew Stenger  /  January 25, 2023

As reported in the Journal of Clinical Oncology by Pieter Sonneveld, MD, PhD, of Erasmus MC Cancer Institute, Rotterdam, the Netherlands, and colleagues, the final overall survival analysis of the phase III CASTOR trial has shown a significant benefit of the addition of daratumumab to bortezomib/dex...

Colorectal Cancer
Genomics/Genetics

Adagrasib With or Without Cetuximab in Previously Treated Patients With Metastatic Colorectal Cancer and a KRAS G12C Mutation

Matthew Stenger  /  February 10, 2023

In a phase I/II trial (KRYSTAL-1) reported in The New England Journal of Medicine, Rona Yaeger, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that the KRAS G12C inhibitor adagrasib showed activity alone and in combination with cetuximab in heavily pretreated patients ...

Immunotherapy

Cardiovascular Events Before and After Initiation of Immune Checkpoint Inhibitor Therapy for Cancer

Matthew Stenger  /  January 25, 2023

In a study reported in JACC: CardioOncology, Lavanya Kondapalli, MD, of the University of Colorado School of Medicine, Aurora, and colleagues found that cardiovascular events common in the general population were observed both prior to and after the initiation of immune checkpoint inhibitor therapy ...

Immunotherapy

Risks of Cardiovascular and Immune-Related Adverse Events in Immune Checkpoint Inhibitor Therapy

Matthew Stenger  /  January 25, 2023

In a single academic hospital network retrospective case-control study reported in JACC:CardioOncology, Charlotte Lee, MD, of Columbia University Irving Medical Center, New York, along with senior author Tomas Neilan, MD, MPH, of Massachusetts General Hospital and colleagues found that patients with...

Skin Cancer
Genomics/Genetics
Immunotherapy

Study Explores the Addition of First-Line Atezolizumab in BRAF V600–Mutant Advanced Melanoma

Matthew Stenger  /  January 25, 2023

As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but statist...

Advertisement

Advertisement




Advertisement